Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BrightPath Biotherapeutics CoTSE:4594 35 Interest Coverage is 74.00 as of Mar. 2026, which is 99% below its 10-year median of 10,000.00. GuruFocus rates TSE:4594 with a GF Score™ of 35/100. The stock has 3 warning signs investors should review. Among 379 Biotechnology companies, BrightPath Biotherapeutics Co ranks worse than 263851.98% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. BrightPath Biotherapeutics Co's
Operating Income
for the
three
months ended in Mar. 2026 was 円126.17 Mil. BrightPath Biotherapeutics Co's Interest Expense for the
three
months ended in Mar. 2026 was 円-1.71 Mil.
BrightPath Biotherapeutics Co's interest coverage for the quarter that ended in Mar. 2026 was 74.00.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for BrightPath Biotherapeutics Co's Interest Coverage or its related term are showing as below:
TSE:4594's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 92.44 * Ranked among companies with meaningful Interest Coverage only.
BrightPath Biotherapeutics Co (TSE:4594) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
BrightPath Biotherapeutics Co Interest Coverage Related Terms
BrightPath Biotherapeutics Co Interest Coverage Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BrightPath Biotherapeutics Co Interest Coverage Chart
TSE:4594 vs VRTX, REGN, RVMD: Interest Coverage Comparison
For the Biotechnology subindustry, BrightPath Biotherapeutics Co's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BrightPath Biotherapeutics Co Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BrightPath Biotherapeutics Co's Interest Coverage distribution charts can be found below:
* The bar in red indicates where BrightPath Biotherapeutics Co's Interest Coverage falls into.
BrightPath Biotherapeutics Co Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BrightPath Biotherapeutics Co (TSE:4594) has a Interest Coverage of 74.00 as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on BrightPath Biotherapeutics Co and its competitors. This is 99% below median its historical median of 10,000.00. According to the industry distribution chart, BrightPath Biotherapeutics Co ranks #999999 out of 379 companies in the Biotechnology industry.
Is BrightPath Biotherapeutics Co's Interest Coverage too high?
BrightPath Biotherapeutics Co's current Interest Coverage of 74.00 is 99% below median its 10-year median of 10,000.00. The Biotechnology industry median Interest Coverage is 92.44. BrightPath Biotherapeutics Co's value of 74.00 is 19.9% below this industry median. Based on the distribution chart, BrightPath Biotherapeutics Co ranks #999999 out of 379 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BrightPath Biotherapeutics Co has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does BrightPath Biotherapeutics Co's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BrightPath Biotherapeutics Co ranks #999999 out of 379 companies for Interest Coverage. This places BrightPath Biotherapeutics Co in the lower half of its industry. The industry median Interest Coverage is 92.44. BrightPath Biotherapeutics Co's value of 74.00 is 19.9% below this benchmark. While the company's 10-year median is 10,000.00 vs. the industry median of 92.44, BrightPath Biotherapeutics Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 92.44, based on 379 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BrightPath Biotherapeutics Co's current Interest Coverage of 74.00 is 19.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on BrightPath Biotherapeutics Co and its competitors. For the Biotechnology industry, the median Interest Coverage is 92.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BrightPath Biotherapeutics Co's current Interest Coverage is 74.00, which is 99% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BrightPath Biotherapeutics Co stock overvalued right now?
BrightPath Biotherapeutics Co (TSE:4594) has a current Interest Coverage of 74.00. The current Interest Coverage is 74.00, which is 99% below median its 10-year median of 10,000.00 and 19.9% below the Biotechnology industry median of 92.44. BrightPath Biotherapeutics Co's overall GF Score™ is 35/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For BrightPath Biotherapeutics Co (TSE:4594), the current Interest Coverage is 74.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BrightPath Biotherapeutics Co Ltd is a biopharmaceutical venture company. It is engaged in developing novel cancer immunotherapeutics. Its products include two candidate products: ITK-1 and GRN-1201 which are in the clinical trial stage.
35GF Score
Get the complete analysis for TSE:4594
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4594 has been successfully added to your 
